LAS VEGAS, Jan. 24, 2018 -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company," "CV Sciences," "our" or "we"), today announced that it will be exhibiting its industry-dominating brand of hemp-derived CBD oil finished products, PlusCBD Oil™, at the 2018 Integrative Health Symposium, held on February 22-24, 2018 at the New York Hilton Midtown, NY in New York, New York. This will be the Company’s second year exhibiting at this cutting-edge integrative practitioner conference.
The Integrative Healthcare Symposium Annual Conference is where multidisciplinary practitioners come together as a cohesive community. Attendees gather each year to connect, learn, collaborate, and return to their practices with insights and techniques they can immediately incorporate into their patient practice. This evidence-based medical conference program is designed to educate, inspire and engage integrative practitioners and those interested in learning more about alternative and complementary approaches to healthcare.
VISIT BOOTH 1011: CV Sciences invites attendees to visit Booth 1011 to learn more about their botanical-based CBD product line. The Company will additionally feature its brand of practitioner-exclusive products available only to healthcare providers nationwide. Also, CV Sciences will be offering exclusive trade show discounts and show specials to practitioners attending the show.
EXHIBITOR-SPONSORED PRESENTATION: Join the CV Sciences team for an interactive presentation, "Hemp-derived CBD: A Review of the Endocannabinoid System, Pharmacokinetic and Pharmacodynamic Concepts," on Friday, February 23th, 2018 at 5:15pm in the Clinton Suite at the New York Hilton Midtown. Presented by Stuart Tomc, VP of Human Nutrition at CV Sciences and Hector Lopez, MD, Scientific Advisor to the Company, the presentation will cover the interactions of CBD and the human endocannabinoid system as it relates to human health, basic pharmacokinetic and pharmacodynamic concepts related to phytocannabinoids-rich extracts of agricultural hemp cultivar Cannabis Sativa L., and what to look for when vetting hemp CBD brands.
NATURAL PARTNERS PANEL: CV Sciences is honored to participate in practitioner wholesale distributor Natural Partners' Roundtable Panel entitled, "CBD: State of the Science, Clinical Applications and What We Know," on Saturday, February 24th, 2018 at 7:30am in the Clinton Suite at the New York Hilton Midtown. CV Sciences’ Advisor, Dr. Hector Lopez, along with a variety of panelists, will be covering various discussion topics around the hemp CBD conversation: from sourcing to quality control to clinical applications. Attendees are encouraged to come early as seating is limited.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
CONTACT:
Robert Haag, Managing Director
IRTH Communications
[email protected]
866-976-4784


Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Instagram Outage Disrupts Thousands of U.S. Users
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 



